|
1
|
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
|
N Engl J Med
|
2010
|
27.12
|
|
2
|
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
|
J Clin Oncol
|
2006
|
6.55
|
|
3
|
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
|
J Clin Oncol
|
2009
|
4.05
|
|
4
|
Severe acute interstitial pneumonia and gefitinib.
|
Lancet
|
2003
|
3.94
|
|
5
|
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth.
|
J Clin Invest
|
2005
|
2.20
|
|
6
|
Methylation of the KEAP1 gene promoter region in human colorectal cancer.
|
BMC Cancer
|
2012
|
2.01
|
|
7
|
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
|
J Clin Oncol
|
2008
|
1.88
|
|
8
|
Consensus statement for the diagnosis and treatment of drug-induced lung injuries.
|
Respir Investig
|
2013
|
1.70
|
|
9
|
Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model.
|
Mol Ther
|
2010
|
1.39
|
|
10
|
Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells.
|
Stem Cells
|
2007
|
1.35
|
|
11
|
Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization.
|
Mol Med
|
2011
|
1.31
|
|
12
|
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth.
|
Cancer Res
|
2002
|
1.22
|
|
13
|
OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice.
|
J Clin Invest
|
2007
|
1.21
|
|
14
|
High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer.
|
Oncology
|
2002
|
1.04
|
|
15
|
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
|
J Thorac Oncol
|
2011
|
1.03
|
|
16
|
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.
|
Cancer Res
|
2004
|
1.01
|
|
17
|
Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1.
|
Mol Ther
|
2011
|
0.99
|
|
18
|
Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
|
Eur J Immunol
|
2006
|
0.99
|
|
19
|
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
|
Oncologist
|
2012
|
0.98
|
|
20
|
Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules.
|
Cancer Sci
|
2003
|
0.98
|
|
21
|
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
|
Tohoku J Exp Med
|
2008
|
0.95
|
|
22
|
Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
|
Clin Cancer Res
|
2005
|
0.93
|
|
23
|
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
|
Oncology
|
2011
|
0.92
|
|
24
|
Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
0.90
|
|
25
|
Involvement of fractalkine/CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila.
|
Infect Immun
|
2005
|
0.90
|
|
26
|
Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
|
Jpn J Clin Oncol
|
2008
|
0.88
|
|
27
|
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601.
|
Lung Cancer
|
2013
|
0.87
|
|
28
|
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells.
|
Eur J Immunol
|
2005
|
0.86
|
|
29
|
Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors.
|
Mol Med
|
2009
|
0.85
|
|
30
|
Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy.
|
Mol Ther
|
2002
|
0.84
|
|
31
|
[A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)].
|
Gan To Kagaku Ryoho
|
2010
|
0.81
|
|
32
|
Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients.
|
Eur J Immunol
|
2003
|
0.80
|
|
33
|
A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.
|
Lung Cancer
|
2006
|
0.79
|
|
34
|
A change in the number of CCSP(pos)/SPC(pos) cells in mouse lung during development, growth, and repair.
|
Respir Investig
|
2013
|
0.79
|
|
35
|
N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers.
|
Oncogene
|
2003
|
0.78
|
|
36
|
A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
|
J Thorac Oncol
|
2006
|
0.76
|
|
37
|
Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
0.76
|
|
38
|
Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study.
|
Oncol Lett
|
2011
|
0.75
|
|
39
|
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.
|
Cancer Sci
|
2008
|
0.75
|
|
40
|
Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
|
Cancer Res
|
2004
|
0.75
|
|
41
|
[Management of adverse effects of standard regimens for small cell lung cancer].
|
Nihon Rinsho
|
2015
|
0.75
|
|
42
|
[Change in patient satisfaction in outpatient chemotherapy unit--comparison in 2005 and 2008].
|
Gan To Kagaku Ryoho
|
2009
|
0.75
|
|
43
|
[Survey on the compliance of patients with continuous infusion of 5-fluorouracil via portable infusion pumps].
|
Gan To Kagaku Ryoho
|
2010
|
0.75
|
|
44
|
Adenocarcinoma with epidermal growth factor receptor gene mutations in three siblings.
|
J Thorac Oncol
|
2008
|
0.75
|
|
45
|
[A case of gastric cancer treated with modified docetaxel, cisplatin and 5-fluorouracil(mDCF)with ingestion inability].
|
Gan To Kagaku Ryoho
|
2012
|
0.75
|
|
46
|
[A case of pulmonary Langerhans cell histiocytosis discovered by CT mass screening and followed by bronchoalveolar lavage].
|
Nihon Kokyuki Gakkai Zasshi
|
2006
|
0.75
|
|
47
|
[Standard chemotherapy of solid tumors. 1) Cancers of the respiratory system and breast].
|
Nihon Naika Gakkai Zasshi
|
2009
|
0.75
|